Tag: Business and Industry

Global Heart Hub and Novartis partner to tackle ASCVD, a global health crisis and world’s #1 killer

October 20, 2021todi0

Global Heart Hub and Novartis announced the launch of the Invisible Nation program. Invisible Nation will bring together a worldwide network of patient organizations and other stakeholders in the cardiovascular (CV) space committed to effecting systemic change in the management of atherosclerotic cardiovascular disease (ASCVD). The program aims to prevent many of the 15 million […]

17 million doses of Johnson & Johnson COVID-19 vaccine to be donated to African Union countries

October 19, 2021todi0

Johnson & Johnson welcomes the U.S. government’s decision to donate 17 million doses of the Johnson & Johnson COVID-19 single-shot vaccine to countries in the African Union (AU). The United States is providing these doses through COVAX, committed to the AU, under an agreement signed recently by the U.S. government, Johnson & Johnson, and Gavi, […]

Petrovax Pharm is taking part in the international pharmaceutical exhibition CPhI Worldwide-2021

October 19, 2021todi0

Petrovax Pharm, the Russian biopharmaceutical company, will participate in CPhI Worldwide-2021 – the international specialized pharmaceutical industry exhibition. This year, it will be held from 9 to 11 November in Italy (Milan) on the territory of the largest exhibition complex Fiera Milano. At the exhibition stand, Petrovax Pharm will present own original pharmaceutical products, that […]

Roche’s anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer’s disease

October 13, 2021todi0

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s disease (AD). This designation is based on data showing that gantenerumab significantly reduced brain amyloid plaque, […]

Positive results from the first study of high-dose influenza vaccine with a COVID-19 mRNA booster support co-administration recommendations

October 11, 2021todi0

Interim results from the first co-administration descriptive study of Sanofi’s Fluzone® High-Dose Quadrivalent vaccine with Moderna’s COVID-19 mRNA investigational booster dose show that the administration of the vaccines at the same visit had similar immunogenicity responses and a similar safety and tolerability profile compared to each vaccine administered individually. Fluzone® High-Dose Quadrivalent is a high-dose […]

GSK welcomes WHO recommendation for broad roll-out of its RTS,S/AS01e (RTS,S) malaria vaccine

October 6, 2021todi0

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK’s RTS,S malaria vaccine to reduce childhood illness and deaths from malaria in children living in sub-Saharan Africa and other regions with moderate to high transmission as defined by WHO.

AZD7442 request for Emergency Use Authorization for COVID-19 prophylaxis filed in US

October 5, 2021todi0

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) combination, for prophylaxis of symptomatic COVID-19. If granted, AZD7442 would be the first LAAB to receive an EUA for COVID-19 prevention. It is the first LAAB with Phase III data […]

Pfizer and BioNTech receive CHMP positive opinion for COVID-19 vaccine booster in the European Union

October 4, 2021todi0

Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on the administration of the companies’ COVID-19 vaccine as a booster dose at least six months after the second dose in individuals […]

Phase II/III trial shows Ronapreve™ (casirivimab and imdevimab) significantly reduces viral load in patients hospitalised with COVID-19

September 30, 2021todi0

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospitalised with COVID-19. The trial met its primary endpoint, showing that Ronapreve significantly reduced viral load within seven days of treatment in patients who had not mounted a natural antibody response of […]

Sanofi to focus its COVID-19 development efforts on the recombinant vaccine candidate

September 29, 2021todi0

Recent positive interim results of Sanofi’s mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company’s platform robust capabilities and strategy in mRNA. Taking into account public health needs and given sufficient mRNA COVID-19 vaccines supply can be expected going forward, Sanofi has decided not to pursue the development of its COVID-19 mRNA candidate into […]